Cargando…
Reconceptualization of the Erlangen Score for the Assessment of Dementia Risk: The ERlangen Score
BACKGROUND: The established Erlangen Score (ES) for the interpretation of cerebrospinal fluid (CSF) biomarkers in the diagnostics of Alzheimer’s disease (AD) uses markers of amyloidopathy and tauopathy, equally weighted to form an easy-interpretable ordinal scale. However, these biomarkers are not e...
Autores principales: | Utz, Janine, Olm, Pauline, Jablonowski, Johannes, Siegmann, Eva-Maria, Spitzer, Philipp, Lewczuk, Piotr, Kornhuber, Johannes, Maler, Juan Manuel, Oberstein, Timo Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657695/ https://www.ncbi.nlm.nih.gov/pubmed/37742651 http://dx.doi.org/10.3233/JAD-230524 |
Ejemplares similares
-
Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects
por: Somers, Charisse, et al.
Publicado: (2019) -
Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease
por: Baldeiras, Inês, et al.
Publicado: (2019) -
Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy
por: Oberstein, Timo Jan, et al.
Publicado: (2022) -
PASSED: Brain atrophy in non-demented individuals in a long-term longitudinal study from two independent cohorts
por: Haas, Anna-Lena, et al.
Publicado: (2023) -
Le programme d'Erlangen
por: Klein, Felix
Publicado: (1974)